DV
Dividend Vision

ZBIO — Zenas BioPharma, Inc.

Zenas BioPharma, Inc. (ZBIO)

Total return is 62.6% over the past 1.9 years, 21.2 points ahead of SPY at 41.4%. Its deepest 1-year drawdown was 64.8%.

ZBIO is a healthcare equity fund that provides exposure to the biopharmaceutical sector through holdings in companies operating in drug development, manufacturing, and related life sciences activities. The fund is newly launched as of September 2024, with limited operational history and currently unavailable data on distribution frequency, yield profile, and expense ratio. This fund appeals to investors seeking healthcare sector exposure, though prospective investors should note the fund's recent inception and review its prospectus for complete details on holdings, fees, and distribution policy.

ZBIO key facts

Asset type
Stock
Asset class
Equity
Inception date
09/13/2024
Distribution frequency
None
Last close
$29.51
Market cap
$1,903,160,448
Average volume
630000.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-8.49